SWGC
NBIX icon

Summit Wealth Group (Colorado)’s Neurocrine Biosciences NBIX Stock Holding History

Summit Wealth Group (Colorado)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,958
Closed -$255K – 487
2025
Q3 		$255K Buy
+2,958
New +$401K 0.03% 402

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Summit Wealth Group (Colorado)'s NBIX Position: Q4 2025 in Review

Summit Wealth Group (Colorado) sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 2,958 shares — an estimated $255K sold.

Summit Wealth Group (Colorado) first reported a position in NBIX in Q3 2025 and held it in 1 quarter. The position peaked at $255K in Q3 2025. 733 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Summit Wealth Group (Colorado) reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Summit Wealth Group (Colorado) sold 2,958 Neurocrine Biosciences shares in Q4 2025, an estimated $255K.
  • Summit Wealth Group (Colorado) first reported a position in Neurocrine Biosciences in Q3 2025 and held it in 1 quarter.
  • Summit Wealth Group (Colorado)'s Neurocrine Biosciences position peaked at $255K in Q3 2025.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Summit Wealth Group (Colorado)'s 13F filing for Q4 2025, filed 4 Feb 2026.